Eli Lilly & Co
Campaign Finance$25,662,051 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
- Employee Color Block
- PAC Color Block
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- Employee Color Block
- PAC Color Block
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Eli Lilly & Co
Names of Lobbyists
Firm Hired Amount Eli Lilly & Co $103,935,110 Brown & Assoc $0
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Consumer Product Safety,
- Medical Research & Clin Labs,
- Foreign Relations,
- Fed Budget & Appropriations
Most Frequently Disclosed Bills
Bill No. Title H.R.3590 Service Members Home Ownership Tax Act of 2009 H.R.1548 Pathway for Biosimilars Act H.R.1427 Promoting Innovation and Access to Life-Saving Medicine Act S.1695 Biologics Price Competition and Innovation Act of 2007 H.R.1908 Patent Reform Act of 2007 S.1145 Patent Reform Act of 2007 H.R.3200 America's Affordable Health Choices Act of 2009 H.R.5629 Pathway for Biosimilars Act H.R.1249 America Invents Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007
RegulationsMentioned in 148 dockets; Submitted to 11 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Eli Lilly & Co" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Eli Lilly & Co
- Toggle 2 PHMSA Eli Lilly & Company - Exemption - Hazardous Materials - Authorize an Alternative Attendance Method for Cargo Tanks During Loading and Unloading of Class 3 and 8 Hazardous Materials 2005
- Toggle 1 FDA Patent Term Extension Application for ENTEREG® (alvimopan), U.S. Patent No. 5,434,171 2009
- Toggle 1 FDA OTC Nighttime Sleep-Aid, Daytime Sedative, & Stimulant Products-CLOSED 1975
- Toggle 1 FDA Postmarketing Safety Reporting for Combination Products 2008
- Toggle 1 FDA Section 118 Data Requirements for Drugs & Biologics, FDAMA 1998
- Toggle 1 FDA Patent Term Extension Application for ENTEREG® (alvimopan), U.S. Patent No. 5,250,542 2009
- Toggle 1 FDA Patent Term Extension Application for NATROBA™ (spinosad) U.S. Patent No. 6,063,771 2011
- Toggle 1 FDA Medical Devices 1976
- Toggle 1 FAA 2006-NE-19-AD 2006
- Toggle 1 FDA Draft Guidances Relating to the Development of Biosimilar Products; Public Hearing; Request for Comments 2011
Mentions in Document Text
View all mentions data for Eli Lilly & Co
- Toggle 20 PHMSA Railway Progress Institute, Inc. - Hazardous Materials - Exemption - Tank Cars - Various Chemicals 1998
- Toggle 8 FDA NADA/ANADA Notices 2010
- Toggle 5 FDA NADA/ANADA Notices 2011
- Toggle 5 FDA NADA/ANADA Notices 2009
- Toggle 5 FDA Docket Pertains to NADA/ANADA Notices 2008
- Toggle 4 EPA Industrial Combustion Coordinated Rulemaking FACA 2004
- Toggle 4 PHMSA Hazardous Materials Transportation; Registration and Fee Assessment Program 1999
- Toggle 3 FDA Patent Extension for Strattera (atomoxetine hydrochloride), 5,658,590 2003
- Toggle 3 FDA Petition Requesting that the Agency not Approve ANADA 011-557 Before Expiration of the 30-month Stay on March 29, 2011 2009
- Toggle 3 FDA Confirm that FDA Will Stay Approval of ANDA No. 90-040 for 30 Months from November 24, 2009 2010
Federal Spending2 grants
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Eli Lilly & Company||2009||National Institutes Of Health||NYSGXRC:A LARGE SCALE CENTER FOR THE PSI||$9,637,015|
|Eli Lilly & Company||2009||National Institutes Of Health||NYSGXRC:A LARGE SCALE CENTER FOR THE PSI||$7,775,217|
Advisory Committees2 people on 2 committees
Data is based on disclosures required by the Federal Advisory Committee Act (FACA). Matches are based on the occurrence of the company name in the committee member affiliation. Variations in company names may cause some matches to be missed.
The table shows only the top 10 agencies. To search and download raw records from the complete dataset see the FACA data section.
Table shows employees of "Eli Lilly & Co" that sat on federal advisory committees.
- Toggle Department of Health and Human Services 2 people on 2 committees